Research programme: ERK1/2 inhibitors - GEn1E Lifesciences
Alternative Names: Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) immunomodulators - GEn1E LifesciencesLatest Information Update: 03 Feb 2023
At a glance
- Originator University of Maryland, Baltimore
- Developer GEn1E Lifesciences
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Lung disorders; Musculoskeletal disorders
Most Recent Events
- 26 Jul 2022 GEn1E Lifesciences in-licenses Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) immunomodulators programme from University of Maryland, Baltimore
- 26 Jul 2022 Early research in Cancer in USA (unspecified route) before January 2023
- 26 Jul 2022 Early research in Lung disorders in USA (unspecified route)